A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).

Yael P MosséElizabeth FoxDavid C HallJoel M ReidStephanie L SafgrenHernan CarolRichard B LockPeter J HoughtonMalcolm A SmithDavid HallDonald A BarkauskasMark KrailoStephan D VossStacey L BergSusan M BlaneyBrenda J Weigel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Despite alisertib activity in pediatric xenograft models and cogent pharmacokinetic-pharmacodynamic relationships in preclinical models and adults, the objective response rate in children and adolescents receiving single-agent alisertib was less than 5%.

Keyphrases

phase ii study
young adults
open label
acute myeloid leukemia
palliative care
locally advanced
bone marrow
randomized controlled trial
stem cells
study protocol
squamous cell carcinoma
cell therapy
rectal cancer